文献速递脊柱关节炎

Deucravacitinib(一种选择性TYK2抑制剂)治疗银屑病关节炎:2期试验中最小疾病活动度各组分的达成情况

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项2期试验的事后分析纳入203例银屑病关节炎患者,随机接受安慰剂、deucravacitinib 6 mg或12 mg每日一次治疗。治疗16周时,deucravacitinib两个剂量组达到最小疾病活动度(MDA)各组分阈值的患者比例均高于安慰剂组,MDA应答率也更高。

要点

  • 基线时无患者满足复合MDA标准,但部分患者满足个别MDA组分标准,各治疗组间总体均衡。
  • 16周内deucravacitinib治疗在所有MDA组分上较安慰剂的平均降幅在数值上更大。
  • 第16周时,deucravacitinib两个剂量组达到各MDA组分阈值的患者比例均高于安慰剂组。

核心结论

  • 治疗16周后,接受deucravacitinib治疗的患者中达到MDA各组分阈值的比例高于安慰剂组,MDA应答率也更高。

研究设计与样本

  • 此项为2期试验(NCT03881059)的事后分析,203例患者按1:1:1随机接受安慰剂、deucravacitinib 6 mg或deucravacitinib 12 mg每日一次治疗。
  • 评估至第16周达到MDA及7个MDA组分各自阈值的患者比例。

主要发现

  • 基线时无患者满足复合MDA标准,部分患者满足个别MDA组分标准,各组分在所有治疗组间总体均衡。
  • 16周治疗期间,deucravacitinib治疗在所有MDA组分上较安慰剂的基线平均降幅在数值上更大。
  • 第16周时,deucravacitinib任一剂量组达到各MDA组分阈值的患者比例均高于安慰剂组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious than placebo across multiple endpoints, including achieving minimal disease activity (MDA). This post hoc analysis further evaluated the achievement of individual components of the MDA criteria with deucravacitinib treatment and the time course of responses in the phase 2 trial. METHODS: Patients (N = 203) were randomized 1:1:1 to once daily treatment with placebo, deucravacitinib 6 mg or deucravacitinib 12 mg. The proportions of patients achieving MDA and each of the seven individual MDA components through week 16 were assessed. RESULTS: At baseline, although some patients met criteria for individual MDA components, none of the patients met the composite MDA criterion, and all components were balanced overall across treatment arms. Treatment with deucravacitinib was associated with a numerically greater mean reduction from baseline in all MDA components vs placebo over 16 weeks of treatment. At week 16, a greater percentage of patients treated with either dose of deucravacitinib vs placebo achieved the threshold criteria for meeting MDA in each of the components. CONCLUSIONS: More patients treated with deucravacitinib met each of the MDA components vs placebo, along with a higher rate of MDA response, after 16 weeks of treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kavanaugh A, Coates LC, Mease PJ, et al. Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial. Rheumatology (Oxford). 2025. PMID: 39423145. doi:10.1093/rheumatology/keae580

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。